Acute and chronic neutral endopeptidase inhibition and the natriuretic response to acute volume expansion

European Journal of Pharmacology

Volumn 347, Issue 2-3, 1998, Pages 245-252

  Scheuermann, Michaela ^a   Dietz, Rainer ^a   Willenbrock, Roland ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Franz Volhard Klinik   (Germany)

Author keywords

ANP (Atrial natriuretic peptide); cGMP; Diuresis; Natriuresis; Neutral endopeptidase inhibition

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; MEMBRANE METALLOENDOPEPTIDASE; METALLOPROTEINASE INHIBITOR; N (2 MERCAPTOMETHYL 3 PHENYLPROPIONYL) BETA ALANINE; N [1 [(2,2 DIMETHYL 1,3 DIOXOLAN 4 YL)METHOXYCARBONYL] 2 PHENYLETHYL]PHENYLALANYL BETA ALANINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VOLUME; CONTROLLED STUDY; ENZYME INHIBITION; FLUID BALANCE; HORMONE BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NATRIURESIS; PRIORITY JOURNAL; RAT; SODIUM BALANCE; SODIUM RETENTION;

ALANINE; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; BODY WEIGHT; CYCLIC GMP; DIURESIS; ENZYME INHIBITORS; HEART RATE; HEMODYNAMIC PROCESSES; KIDNEY; MALE; NATRIURESIS; NEPRILYSIN; RATS; RATS, WISTAR;

EID: 0032562385     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00106-X     Document Type: Article

References (44)

1. Abassi Z.A., Kotob S., Golomb E., Pieruzzi F., Keiser H.R. Pulmonary and renal neutral endopeptidase EC 3.4.24.11 in rats with experimental heart failure. Hypertension. 25:1995;1178-1184.
2. Allgren R.L., Marbury T.C., Rahman N., Weisberg L.S., Fenves A.Z., Lafayette R.A., Sweet R.M., Genter F.C., Kurnik B.R.C., Conger J.D., Sayegh M.H. Anaritide in acute tubular necrosis. New Engl. J. Med. 336:1997;828-834.
3. Aronoff F.T., Benade J.E., Brunner H.R., DiBona G.F., Fleischhauer T., Lam M., Lawton W.J., Luft F.C., Martinez-Maldonado M. Renal and hemodynamic effects of atrial natriuretic peptide in patients with cirrhosis. Am. J. Med. Sci. 299:1990;2-9.
4. Awazu M., Ichikawa I. Biological significance of atrial natriuretic peptide in the kidney. Nephron. 63:1993;1-14.
5. Burnier M., Ganslmayer M., Perret F., Porchet M., Kosoglou T., Gould A., Nussberger J., Waeber B., Brunner H.R. Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers. Clin. Pharmacol. Ther. 50:1991;181-191.
6. Cavero P.G., Margulies K.B., Winaver J., Seymour A.A., Delaney N.G., Burnett J.C. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation. 82:1990;196-201.
7. Danilewicz J.C., Barclay P.L., Barnish I.T., Brown D., Cambell S.F., James K., Samuels G.M.R., Terrett N.K., Wythes M.J. UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem. Biophys. Res. Commun. 164:1989;58-65.
8. De Zeeuw D., Janssen W.M.T., De Jong P.E. Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int. 41:1992;1115-1133.
9. DeNicola L., Bellizzi V., Cianciaruso B., Minutolo R., Colucci G., Balletta M., Fuiano G., Conte G. Pathophysiological role and diuretic efficacy of atrial natriuretic peptide in renal patients. J. Am. Soc. Nephrol. 8:1997;445-455.
10. ös and Skidgel, 1989.
11. Erdös E.G., Skidgel R.A. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 3:1989;145-151.
12. Favrat B., Burnier M., Nussberger J., Lecomte J.M., Brouard R., Waeber B., Brunner H.R. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J. Hypertens. 13:1995;797-804.
13. Garcia R., Cantin M., Thibault G. Role of right and left atria in natriuresis and atrial natriuretic factor release during blood volume changes in the conscious rat. Circulation. 61:1987;99-106.
14. Graf K., Koehne P., Gräfe M., Zhang M., Auch-Schwelk W., Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension. 26:1995;230-235.
15. Gutkowska J., Bonan R., Roy D., Bourassa M., Garcia R., Thibault G., Genest J., Cantin M. Atrial natriuretic factor in human plasma. Biochem. Biophys. Res. Commun. 139:1986;287-295.
16. Hamet P., Tremblay J., Pang St.C., Garcia R., Thibault G., Gutkowska J., Cantin M., Genest J. Effect of native and synthetic atrial natriuretic factor on cyclic GMP. Biochem. Biophys. Res. Commun. 123:1984;515-527.
17. Hamet P., Tremblay J., Pang St.C., Skuherska R., Schiffrin E.L., Garcia R., Cantin M., Genest J., Palmour R., Ervin F.R., Martin St., Goldwater R. Cyclic GMP as mediator and biological marker of atrial natriuretic factor. J. Hypertens. 4:1986;S49-S56.
18. Helin K., Tikkanen T., Saijonmaa O., Sybertz E.J., Vernulapalli S., Sariola H., Fyhrquist F. Prolonged neutral endopeptidase inhibition in heart failure. Eur. J. Pharmacol. 198:1991;23-30.
19. Inagami T. Atrial natriuretic factor. J. Biol. Chem. 264:1989;3043-3046.
20. Kabayama Y., Fukamachi Y., Kamisaki T., Tanaka H. Stimulation by volume expansion of atrial natriuretic peptide release from perfused rat heart. Peptides. 8:1987;257-260.
21. Koepke J.P., Tyler L.D., Trapani A.J., Bovy P.R., Spear K.L., Olins G.M., Blaine E.H. Interaction of non-guanylate cyclase-linked atriopeptin receptor ligand and endopeptidase inhibitor in conscious rats. J. Pharmacol. Exp. Ther. 249:1989;172-176.
22. Koller K.J., Goeddel D.V. Molecular biology of the natriuretic peptides and their receptors. Circulation. 86:1992;1081-1088.
23. Kukkonen P., Vuolteenaho O., Ruskoaho H. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand. Endocrinology. 130:1992;755-765.
24. Lewis H.M., Wilkins M.R., Selwyn B.M., Yelland U.J., Griffith M.E., Bhoola K.D. Urinary guanosine 3′:5′-cyclic monophosphate but not tissue kallikrein follows the plasma atrial natriuretic factor response to acute volume expansion with saline. Clin. Sci. 75:1988;489-494.
25. Maack T., Suzuki M., Almeida F.A., Nussenzveig D., Scarborough R.M., McEnroe G.A., Lewicki J.A. Physiological role of silent receptors of atrial natriuretic factor. Science. 238:1987;675-678.
26. Margulies K.B., Heublein D.M., Perrella M.A., Burnett J.C. ANF-mediated renal cGMP generation in congestive heart failure. Am. J. Physiol. 260:1991;562-568.
27. Margulies K.B., Perrella M.A., McKinley L.J., Burnett J.C. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J. Clin. Invest. 88:1991;1636-1642.
28. Monopoli A., Ongini E., Cigola E., Olivetti G. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 20:1992;496-504.
29. Richards A.M., Wittert G., Espiner E.A., Yandle T.G., Frampton C., Ikram H. Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects. J. Hypertens. 9:1991;955-962.
30. Richards A.M., Wittert G.A., Grozier I.A., Espiner E.A., Yandle T.G., Ikram H., Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J. Hypertens. 11:1993;407-416.
31. Richman R.A., Kopf G.S., Hamet P., Johnson R.A. Preparation of cyclic nucleotide antisera with thyroglobulin-cyclic nucleotide conjugates. J. Cyclic Nucleotide Res. 6:1980;461-468.
32. Roy L.F., Ogilvie R.I., Larochelle P., Hamet P., Leenen F.H.H. Cardiac and vascular effects of atrial natriuretic factor and sodium nitroprusside in healthy men. Circulation. 79:1989;383-392.
33. Sagnella G.A., Singer D.R.J., Markandu N.D., MacGregor G. Atrial natriuretic peptide - cyclic GMP coupling and urinary sodium excretion during acute volume expansion in man. Can. J. Physiol. Pharmacol. 68:1990;535-538.
34. Sagnella G.A., Singer D.R.J., Markandu N.D., Buckley M.G., MacGregor G.A. Is atrial natriuretic peptide-guanosine 3′,5′ cyclic monophosphate coupling a determinant of urinary sodium excretion in essential hypertension? J. Hypertens. 10:1992;349-354.
35. Scott J.M., Barclay P.L., Shepperson N.B. Renal effects of neutral endopeptidase inhibition in euvolemic and hypervolemic rats. Eur. J. Pharmacol. 242:1993;91-97.
36. Seymour A.A., Norman J.A., Asaad M.M., Fennell S.A., Abboa-Offei B., Little D.K., Kratunis V.J., Delaney N.G., Hunt J.T., Di Donato G. Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors. J. Pharmacol. Exp. Ther. 256:1990;1002-1009.
37. Siragy H.M., Ibrahim M.M., Jaffa A.A., Mayfield R., Margolius H.S. Rat renal interstitial bradykinin, prostaglandin E2, cyclic guanosine 3′,5′-monophosphate. Effects of altered sodium intake. Hypertension. 23:1994;1068-1070.
38. Stasch J.-P., Knorr A., Wegner M., Hirth-Dietrich C. Prolonged inhibition of neutral endopeptidase 24.11 by Sinorphan in stroke-prone spontaneously hypertensive rats. Hypertens. Res. 18:1995;137-143.
39. Sybertz E.J., Chiu P.J.S., Vemulapalli S., Watkins R., Haslanger M.F. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. Hypertension. 15:1990;152-161.
40. Tremblay, J., Willenbrock, R., Cusson, J.R., Larochelle, P., Schiller, P.W., Leenen, F.H.H., Palmour, R., Ervin, F., Testaert, E., Hamet, P., 1988. Role of particulate guanylate cyclase activation in the expression of the biological actions of ANF. In: Needleman, P. (Ed.), Biological and Molecular Aspects of Atrial Factors - UCLA Symposia on Molecular and Cellular Biology. Alan R. Liss, New York, p. 97-108.
41. Trippodo N.C., Gabel R.A., Harvey C.M., Asaad M.M., Rogers W.L. Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats. J. Cardiovasc. Pharmacol. 18:1991;308-316.
42. Ura N., Shimamoto K., Kuroda S., Nomura N., Iwata M., Aoyama T., Iimura O. The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats. Clin. Exp. Hypertens. 16:1994;799-808.
43. Waldman S.A., Rapoport R.M., Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J. Biol. Chem. 259:1984;14332-14334.
44. Willenbrock R., Scheuermann M., Höhnel K., Luft F.C., Dietz R. Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Hypertension. 27:1996;1259-1266.